Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin

  • Takahiro Suzuki
  • Takuma Kagami
  • Takahiro Uotani
  • Mihoko Yamade
  • Yasushi Hamaya
  • Moriya Iwaizumi
  • Satoshi Osawa
  • Ken Sugimoto
  • Hiroaki Miyajima
  • Takahisa Furuta



Vonoprazan, a novel potassium-competitive acid blocker, elicits potent acid inhibition and hypergastrinemia at a dose of 20 mg. Its recommended maintenance dose for gastro-esophageal reflux disease is 10 mg, which is sometimes insufficient for preventing nocturnal acid breakthrough (NAB). Concomitant use of a histamine 2 receptor antagonist (H2RA) is effective for NAB. However, further acid inhibition by addition of H2RA has concern of hypergastrinemia again. Lafutidine (H2RA) is known to stimulate somatostatin release.


The aim of this study is to compare the levels of acid inhibition and serum gastrin attained by addition of lafutidine to vonoprazan 10 mg with levels after a dose increase of vonoprazan from 10 to 20 mg.


Thirteen healthy volunteers underwent 24-h intragastric pH monitoring and serum gastrin measurements on day 7 of three different regimens: vonoprazan 10 mg, vonoprazan 10 mg plus lafutidine 10 mg, and vonoprazan 20 mg.


Median pH 4 holding time ratios (range) by vonoprazan 10 mg, vonoprazan 10 mg plus lafutidine 10 mg, and vonoprazan 20 mg were 82% (47–88%), 88% (76–93%), and 99% (95–100%) while those at nighttime from 10 p.m. to 8 a.m. were 94% (29–100%), 100% (95–100%), and 100%, respectively. The incidences of NAB with vonoprazan 10 mg, vonoprazan plus lafutidine, and vonoprazan 20 mg were 38, 8, and 0%, respectively. Respective serum gastrin levels were 420 (173–508), 323 (196–521), and 504 (400–812) pg/ml.


Addition of lafutidine 10 mg to vonoprazan 10 mg achieved sufficient acid inhibition, especially at nighttime, without further increase of serum gastrin levels.


Potassium-competitive acid blocker Vonoprazan Lafutidine Histamine 2 receptor antagonist Intragastric pH 


pH 4 HRT

pH > 4 holding time ratio


Proton pump inhibitor


  1. 1.
    Sontag SJ (1990) The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin N Am 19:683–712Google Scholar
  2. 2.
    Klinkenberg-Knol EC (1992) The role of omeprazole in healing and prevention of reflux disease. Hepato-Gastroenterology 39(Suppl 1):27–30PubMedGoogle Scholar
  3. 3.
    Massoomi F, Savage J, Destache CJ (1993) Omeprazole: a comprehensive review. Pharmacotherapy 13:46–59PubMedGoogle Scholar
  4. 4.
    Dobrilla G, Di Fede F (1993) Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. Clin Ther 15(Suppl B):2–13PubMedGoogle Scholar
  5. 5.
    Furuta T, Shirai N, Watanabe F et al (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 72:453–460CrossRefPubMedGoogle Scholar
  6. 6.
    Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH (1992) Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 51(Suppl 1):59–67PubMedGoogle Scholar
  7. 7.
    Katz PO, Anderson C, Khoury R, Castell DO (1998) Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 12:1231–1234CrossRefPubMedGoogle Scholar
  8. 8.
    Peghini PL, Katz PO, Bracy NA, Castell DO (1998) Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 93:763–767CrossRefPubMedGoogle Scholar
  9. 9.
    Kagami T, Sahara S, Ichikawa H et al (2016) Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 43:1048–1059CrossRefPubMedGoogle Scholar
  10. 10.
    Sakurai Y, Mori Y, Okamoto H et al (2015) Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects—a randomised open-label cross-over study. Aliment Pharmacol Ther 42:719–730CrossRefPubMedGoogle Scholar
  11. 11.
    Ashida K, Sakurai Y, Hori T et al (2016) Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 43:240–251CrossRefPubMedGoogle Scholar
  12. 12.
    Jianu CS, Fossmark R, Viset T et al (2012) Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 36:644–649CrossRefPubMedGoogle Scholar
  13. 13.
    Nandy N, Hanson JA, Strickland RG, McCarthy DM (2016) Solitary gastric carcinoid tumor associated with long-term use of omeprazole: a case report and review of the literature. Dig Dis Sci 61:708–712CrossRefPubMedGoogle Scholar
  14. 14.
    Jianu CS, Lange OJ, Viset T et al (2012) Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 47:64–67CrossRefPubMedGoogle Scholar
  15. 15.
    Fossmark R, Sagatun L, Nordrum IS, Sandvik AK, Waldum HL (2015) Hypergastrinemia is associated with adenocarcinomas in the gastric corpus and shorter patient survival. APMIS : Acta Pathol Microbiol Immunol Scand 123:509–514CrossRefGoogle Scholar
  16. 16.
    Sugimoto M, Furuta T, Shirai N et al (2005) Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin Pharmacol Ther 77:302–311CrossRefPubMedGoogle Scholar
  17. 17.
    Katsube T, Adachi K, Kawamura A et al (2000) Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 14:1049–1056CrossRefPubMedGoogle Scholar
  18. 18.
    Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO (2001) Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 15:1351–1356CrossRefPubMedGoogle Scholar
  19. 19.
    Tari A, Yamamoto G, Sumii K et al (1993) Role of histamine 2 receptor in increased expression of rat gastric H(+)-K(+)-ATPase alpha-subunit induced by omeprazole. Am J Phys 265:G752–G758Google Scholar
  20. 20.
    Yamamoto G, Tari A, Sumii K, Sumii M, Haruma K, Kajiyama G (1995) Famotidine, a histamine-2-receptor antagonist, inhibits the increase in rat gastric H+/K(+)-ATPase mRNA induced by intravenous infusion of gastrin 17 and histamine. Dig Dis Sci 40:2064–2069CrossRefPubMedGoogle Scholar
  21. 21.
    Ichikawa T, Ota H, Sugiyama A et al (2007) Effects of a novel histamine H2-receptor antagonist, lafutidine, on the mucus barrier of human gastric mucosa. J Gastroenterol Hepatol 22:1800–1805CrossRefPubMedGoogle Scholar
  22. 22.
    Nakano M, Kitano S, Nanri M, Kiniwa M (2011) Lafutidine, a unique histamine H2-receptor antagonist, inhibits distention-induced gastric acid secretion through an H2 receptor-independent mechanism. Eur J Pharmacol 658:236–241CrossRefPubMedGoogle Scholar
  23. 23.
    Sano T, Utsumi D, Amagase K et al (2017) Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons. J Physiol Pharmacol: Off J Polish Physiol Soc 68:79–90Google Scholar
  24. 24.
    Kim EH, Lee YC, Chang YW et al (2015) Efficacy of lafutidine versus famotidine in patients with reflux esophagitis: a multi-center, randomized, double-blind, non-inferiority phase III trial. Dig Dis Sci 60:1724–1732CrossRefPubMedGoogle Scholar
  25. 25.
    Itoh H, Naito T, Takeyama M (2002) Lafutidine changes levels of somatostatin, calcitonin gene-related peptide, and secretin in human plasma. Biol Pharm Bull 25:379–382CrossRefPubMedGoogle Scholar
  26. 26.
    Sakurai K, Suda H, Ido Y et al (2017) Comparative study: vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 23:668–675CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Sugano K (2015) Vonoprazan: a novel potassium-competitive acid blocker. Nihon rinsho Jpn J Clin Med 73:1163–1168Google Scholar
  28. 28.
    Lanzon-Miller S, Pounder RE, Chronos NA, Raymond F, Hamilton MR, Dalgleish D (1988) Twenty four hour intragastric acidity and plasma gastrin concentration in healthy volunteers taking nizatidine 150 mg, nizatidine 300 mg, ranitidine 300 mg, or placebo at 21:00 h. Gut 29:1364–1369CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Mohammed R, Holden RJ, Hearns JB, McKibben BM, Buchanan KD, Crean GP (1983) Effects of eight weeks’ continuous treatment with oral ranitidine and cimetidine on gastric acid secretion, pepsin secretion, and fasting serum gastrin. Gut 24:61–66CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Lanzon-Miller S, Pounder RE, Ball SG, Dalgleish DJ, Coward J, Jackson AO (1988) The effects of famotidine, 40 mg at night, on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. Scand J Gastroenterol 23:244–250CrossRefPubMedGoogle Scholar
  31. 31.
    Ikawa K, Shimatani T, Azuma Y, Inoue M, Morikawa N (2006) Calcitonin gene-related peptide and somatostatin releases correlated with the area under the lafutidine concentration-time curve in human plasma. J Clin Pharm Ther 31:351–356CrossRefPubMedGoogle Scholar
  32. 32.
    Freedberg DE, Kim LS, Yang YX (2017) The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 152:706–715CrossRefPubMedGoogle Scholar
  33. 33.
    Larsson H, Hakanson R, Mattsson H, Ryberg B, Sundler F, Carlsson E (1988) Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells. Toxicol Pathol 16:267–272CrossRefPubMedGoogle Scholar
  34. 34.
    Havu N, Mattsson H, Ekman L, Carlsson E (1990) Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 45:189–195CrossRefPubMedGoogle Scholar
  35. 35.
    Larsson H, Carlsson E, Mattsson H et al (1986) Plasma gastrin and gastric enterochromaffin­like cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 90:391–399CrossRefPubMedGoogle Scholar
  36. 36.
    Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G (1986) Pharmacology and toxicology of omeprazole—with special reference to the effects on the gastric mucosa. Scand J Gastroenterol Suppl 118:31–38CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Takahiro Suzuki
    • 1
  • Takuma Kagami
    • 1
  • Takahiro Uotani
    • 2
  • Mihoko Yamade
    • 1
  • Yasushi Hamaya
    • 1
  • Moriya Iwaizumi
    • 3
  • Satoshi Osawa
    • 2
  • Ken Sugimoto
    • 1
  • Hiroaki Miyajima
    • 1
  • Takahisa Furuta
    • 4
  1. 1.First Department of MedicineHamamatsu University School of MedicineHamamatsuJapan
  2. 2.Department of Endoscopic and Photodynamic MedicineHamamatsu University School of MedicineHamamatsuJapan
  3. 3.Department of Laboratory MedicineHamamatsu University School of MedicineHamamatsuJapan
  4. 4.Center for Clinical ResearchHamamatsu University School of MedicineHamamatsuJapan

Personalised recommendations